Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Osteoporosis, Postmenopausal Clear all
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women

NCT00443716
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
estrogen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1985 – 1989
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 6, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of T-cells in Post-Menopausal Osteoporosis

NCT00787904
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 6, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

NCT00688246
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
biologic sample preservation procedure, dual x-ray absorptometry
Other · Procedure
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
13
States / cities
Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 6, 2026, 4:27 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

NCT04964388
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077
View directory record Official record
Conditions
Osteoporosis
Interventions
rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 2Phase 3 Interventional

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

NCT07660536
View directory record Official record
Conditions
Osteoporosis (Senile)
Interventions
doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules)
Drug
Lead sponsor
Creighton University
Other
Eligibility
60 Years to 78 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1994
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Effects of Black Cohosh on Menopausal Hot Flashes

NCT00010712
View directory record Official record
Conditions
Postmenopause, Hot Flashes, Osteoporosis, Postmenopausal
Interventions
Black Cohosh
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
45 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 6, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Open Label Extension

NCT00172120
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Beverly Hills, California • Chicago, Illinois • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 6, 2026, 4:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
AGA2118, Placebo
Drug · Other
Lead sponsor
Angitia Biopharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 6, 2026, 4:27 PM EDT
Completed No phase listed Observational

Circulating miRNA in Primary Hyperparathyroidism

NCT03931109
View directory record Official record
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hesperidin and Bone Health in Postmenopausal Women

NCT01881204
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Hesperidin and Calcilock, Hesperidin, Control
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Touch for Wrist Fractures in Postmenopausal Women

NCT00079521
View directory record Official record
Conditions
Osteoporosis, Fractures
Interventions
Therapeutic Touch
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 85 Years · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 6, 2026, 4:27 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

"PTHrP(1-36) IV Dose Escalation Study"

NCT00177411
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone-related Protein
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 6, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

NCT07365514
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiome, Menopause
Interventions
Blackcurrant (BC) extract, Placebo
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin K and Bone Turnover in Postmenopausal Women

NCT00062595
View directory record Official record
Conditions
Osteoporosis
Interventions
phylloquinone (K1), menatetranone (MK4)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 6, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Preventing Osteoporosis Using Denosumab

NCT02753283
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions
denosumab, Placebo, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 4:27 PM EDT